Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
83 hedge funds and large institutions have $259M invested in Avadel Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 23 increasing their positions, 21 reducing their positions, and 13 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
82% more call options, than puts
Call options by funds: $6.67M | Put options by funds: $3.66M
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
4.81% more ownership
Funds ownership: 54.69% → 59.5% (+4.8%)
2% more funds holding
Funds holding: 81 → 83 (+2)
10% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 21
10% less capital invested
Capital invested by funds: $287M → $259M (-$27.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$11M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$4.9M |
| 3 |
GJL
Gendell Jeffrey L
|
+$3.54M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$1.76M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$1.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$5.92M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$5.53M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.41M |
| 4 |
JP Morgan Chase
New York
|
-$2.02M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.56M |
AVDL Hedge Fund Activity: Q4 2021 in Review
83 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q4 2021, worth a combined $259M — down 9.6% from $287M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new AVDL positions and 13 closed out — a net gain of 3 holders — while 23 added to existing stakes and 21 trimmed.
The largest buyer was Cowen and Company, adding an estimated $11M. The largest seller was Brandes Investment Partners, cutting an estimated $5.92M.
- 83 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q4 2021, up from 81 in Q3 2021.
- Funds reported $259M of Avadel Pharmaceuticals stock for Q4 2021, down 9.6% quarter-over-quarter.
- 16 funds opened new Avadel Pharmaceuticals positions in Q4 2021 and 13 closed out, a net change of +3 holders.
- The largest Avadel Pharmaceuticals buyer in Q4 2021 was Cowen and Company, an estimated $11M added.
- The largest Avadel Pharmaceuticals seller in Q4 2021 was Brandes Investment Partners, an estimated $5.92M sold.
Based on aggregated 13F filings for Q4 2021.